Integrated Wealth Concepts LLC Sells 10,984 Shares of Pfizer Inc. $PFE

Key Points

• Integrated Wealth Concepts LLC reduced its holdings in Pfizer by 2.2%, selling 10,984 shares during the first quarter, leaving them with 481,165 shares valued at approximately $12.2 million.
• Pfizer reported strong earnings, with an EPS of $0.78 for the quarter, surpassing expectations, and its revenue grew by 10.3% year-over-year.
• The company recently announced a quarterly dividend of $0.43, translating to an annual yield of 6.9%, while analysts maintain a consensus price target of $28.12 on its shares.

Integrated Wealth Concepts LLC decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 2.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 481,165 shares of the biopharmaceutical company's stock after selling 10,984 shares during the quarter. Integrated Wealth Concepts LLC's holdings in Pfizer were worth $12,193,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. William B. Walkup & Associates Inc. raised its position in shares of Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after purchasing an additional 454 shares during the period. Members Trust Co increased its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares during the period. Sutton Place Investors LLC increased its position in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after acquiring an additional 472 shares during the period. MSH Capital Advisors LLC increased its position in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after acquiring an additional 485 shares during the period. Finally, Trust Asset Management LLC increased its position in Pfizer by 0.8% during the first quarter. Trust Asset Management LLC now owns 65,183 shares of the biopharmaceutical company's stock worth $1,652,000 after acquiring an additional 490 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.3%

Shares of NYSE:PFE opened at $24.86 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company's fifty day moving average is $24.85 and its 200-day moving average is $24.36. The company has a market capitalization of $141.31 billion, a PE ratio of 13.22, a P/E/G ratio of 0.87 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 EPS. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date was Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Bank of America boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. HSBC dropped their target price on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Citigroup lifted their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.